Sugi Predict

Sugi Predict / Compounds / SCHEMBL6448138

SCHEMBL6448138

SCHEMBL6448138

C=C(C(=O)[C@H](CCc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)N1CCOCC1)S(=O)(=O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 11/20 0.69
▸ CTSB P07858 6/20 0.69
▸ CTSL P07711 5/20 0.69
▸ CTSK P43235 4/20 0.69
▸ CTSH P09668 1/20 0.69
▸ CTSC P53634 1/20 0.69
▸ PSMB5 P28074 3/20 0.49
▸ PSMB11 A5LHX3 2/20 0.49
▸ PSMA7 O14818 2/20 0.49
▸ PSMB1 P20618 2/20 0.49
▸ PSMA1 P25786 2/20 0.49
▸ PSMA2 P25787 2/20 0.49
▸ PSMA3 P25788 2/20 0.49
▸ PSMA4 P25789 2/20 0.49
▸ PSMB8 P28062 2/20 0.49
▸ PSMB9 P28065 2/20 0.49
▸ PSMA5 P28066 2/20 0.49
▸ PSMB4 P28070 2/20 0.49
▸ PSMB6 P28072 2/20 0.49
▸ PSMB10 P40306 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449419 0.91 CTSB (0.67) CTSSCTSBCTSLCTSKCTSH
SCHEMBL6450588 0.87 CTSB (0.62) CTSSCTSBCTSLCTSKCTSH
SCHEMBL7134732 0.82 CTSS (0.72) CTSSCTSBCTSLCTSKCTSH
SCHEMBL7352989 0.81 CTSL (1.00) CTSSCTSBCTSLCTSKCTSH
SCHEMBL7353008 0.81 CTSL (1.00) CTSSCTSBCTSLCTSKCTSH
SCHEMBL7352997 0.81 CTSL (1.00) CTSSCTSBCTSLCTSKCTSH
SCHEMBL7106325 0.81 CTSB (0.57) CTSSCTSBCTSLCTSKCTSH
SCHEMBL7106329 0.81 CTSB (0.57) CTSSCTSBCTSLCTSKCTSH
SCHEMBL6452052 0.80 CTSB (0.58) CTSSCTSBCTSLCTSKCTSH
SCHEMBL6452048 0.80 CTSB (0.58) CTSSCTSBCTSLCTSKCTSH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections DENDREON CORPORATION 2002-08-08 — — US claimed
WO-2013036766-A1 SMALL MOLECULE NAPHTHOQUINONE- AND PHTHALIMIDE-BASED LIPOCATIONS AS ANTI-PARASITIC AGENTS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2013-03-14 — — WO disclosed
WO-2005107470-A2 USE OF CARBONIC ANHYDRASE INHIBITORS FOR INSECT CONTROL AND MALARIA TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2005-11-17 — — WO disclosed
WO-2002048097-A9 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INT INC (US) 2003-05-08 — — WO disclosed
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections DENDREON CORPORATION 2002-08-08 — — US disclosed
WO-2002048097-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INTERNATIONAL, INC. (US) 2002-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections CAT, CTSA, CTRL CTSS 5/4885CTSB 6/4885CTSL 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.